Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics

Deciphera Pharmaceuticals, Inc. (DCPH): $16.06

0.31 (+1.97%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add DCPH to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#42 of 357

in industry

DCPH Price/Volume Stats

Current price $16.06 52-week high $17.69
Prev. close $15.75 52-week low $9.90
Day low $15.78 Volume 328,300
Day high $16.21 Avg. volume 541,114
50-day MA $15.20 Dividend yield N/A
200-day MA $13.74 Market Cap 1.30B

DCPH Stock Price Chart Interactive Chart >

DCPH POWR Grades

  • DCPH scores best on the Value dimension, with a Value rank ahead of 70.87% of US stocks.
  • DCPH's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • DCPH's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).

DCPH Stock Summary

  • The ratio of debt to operating expenses for DECIPHERA PHARMACEUTICALS INC is higher than it is for about just 12.56% of US stocks.
  • With a price/sales ratio of 8.46, DECIPHERA PHARMACEUTICALS INC has a higher such ratio than 87.34% of stocks in our set.
  • DCPH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 16.39% of US stocks.
  • If you're looking for stocks that are quantitatively similar to DECIPHERA PHARMACEUTICALS INC, a group of peers worth examining would be FULC, ADVM, GBIO, SABS, and SPCE.
  • Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.

DCPH Valuation Summary

  • In comparison to the median Healthcare stock, DCPH's price/earnings ratio is 122.98% lower, now standing at -6.7.
  • Over the past 76 months, DCPH's price/earnings ratio has gone up 9.7.

Below are key valuation metrics over time for DCPH.

Stock Date P/S P/B P/E EV/EBIT
DCPH 2023-12-29 8.5 3.4 -6.7 -6.3
DCPH 2023-12-28 8.7 3.4 -6.8 -6.4
DCPH 2023-12-27 8.5 3.4 -6.6 -6.2
DCPH 2023-12-26 8.8 3.5 -6.8 -6.4
DCPH 2023-12-22 8.7 3.4 -6.8 -6.4
DCPH 2023-12-21 8.2 3.3 -6.4 -6.0

DCPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DCPH has a Quality Grade of D, ranking ahead of 19.93% of graded US stocks.
  • DCPH's asset turnover comes in at 0.137 -- ranking 232nd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows DCPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.137 0.980 -0.586
2021-03-31 0.104 0.993 -0.553
2020-12-31 0.062 0.995 -0.544
2020-09-30 0.033 0.996 -0.556
2020-06-30 0.011 0.999 -0.565
2020-03-31 0.044 1.000 -0.565

DCPH Price Target

For more insight on analysts targets of DCPH, see our DCPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $68.50 Average Broker Recommendation 1.36 (Strong Buy)

Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio


Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.


DCPH Latest News Stream


Event/Time News Detail
Loading, please wait...

DCPH Latest Social Stream


Loading social stream, please wait...

View Full DCPH Social Stream

Latest DCPH News From Around the Web

Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

Deciphera Pharmaceuticals CEO Steven Hoerter Sells Over 30,000 Shares

Steven Hoerter, the President and CEO of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH), has recently sold a significant number of shares in the company.

Yahoo | December 15, 2023

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 97% Above Its Share Price

Key Insights The projected fair value for Deciphera Pharmaceuticals is US$29.64 based on 2 Stage Free Cash Flow to...

Yahoo | December 8, 2023

Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

Insider Sell Alert: Daniel Martin of Deciphera Pharmaceuticals Inc Cashes Out Shares

In the realm of biopharmaceuticals, insider trading activity often garners significant attention from investors seeking to understand the internal perspectives of a company's executives.

Yahoo | December 2, 2023

Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2023

Read More 'DCPH' Stories Here

DCPH Price Returns

1-mo 11.92%
3-mo 31.21%
6-mo 10.15%
1-year 12.62%
3-year 48.57%
5-year 123.44%
YTD -0.43%
2023 -1.59%
2022 67.76%
2021 -31.52%
2020 -8.31%
2019 196.52%

Continue Researching DCPH

Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:

Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!